REVIEW ARTICLE Sue Rimes, et al; ONCOLOGY Nurse Edition Vol. 25 No. 10 Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
REVIEW ARTICLE John O. Schorge, et al; ONCOLOGY Vol. 25 No. 10 The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
NEWS & ANALYSIS Anna Azvolinsky, PhD Many doctors do not properly adhere to current guidelines for offering breast and ovarian cancer counseling and testing services to their female patients, according to a recent study from the Division of Cancer Prevention and Control at the CDC. The vignette-based national survey finds that while genetic counseling is recommended for women at high risk for breast and/or ovarian cancer, only 41% of physicians self-reported adhering to recommendations to refer for genetic counseling or testing.
REVIEW ARTICLE Maria Jose Echarri Gonzalez, et al;ONCOLOGY Vol. 25 No. 2 This article reviews the known data on the dose-effect relationship for platinum drugs in ovarian cancer, and explores why interest in platinum drugs has become the central focus of ovarian cancer treatment.
CME Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers. •The Complexity of Hereditary Cancer Syndromes
A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).
While a prominent role for HE4 in these areas remains to be determined, this thorough review of HE4 demonstrates that the biomarker is complementary to, and occasionally more useful than, the widely used CA 125 in the management of gynecologic malignancies. More »
Although the combination of CA-125 and HE4 appears indicated for use in symptomatic patients or in patients with an adnexal mass, there is no evidence that it would be indicated as a screening test in asymptomatic patients. More »
The data on HE4 as a prognosticator in both ovarian and endometrial cancer constitute, at most, an interesting observation, but most likely they are simply a reflection of total tumor burden. There are certainly not enough data to justify making major treatment decisions in ovarian or endometrial cancer on the basis of absolute marker levels. Proteomics and genomics seem more likely to make a difference in this area. More »
A considerable number of women with breast cancer are diagnosed during their reproductive years. In the short period of time in which newly diagnosed women will need to make decisions about surgical options and adjuvant therapy, younger women with breast cancer also face the potential impairment or complete loss of their fertility. More »